Please ensure Javascript is enabled for purposes of website accessibility

Why Odonate Therapeutics Stock Is Crashing Today

By Keith Speights - Mar 22, 2021 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's news was so bad that it's going out of business.

What happened

Shares of Odonate Therapeutics (ODT 0.66%) were crashing 78% as of 11:38 a.m. EDT on Monday. The huge drop came after Odonate announced that it's discontinuing the development of tesetaxel and will "wind down the operations of the Company."

So what

Today's news underscores the risks involved with investing in clinical-stage biotech stocks. The risk is especially great for companies with only one pipeline candidate.

Man wearing a coat and tie holding a red line with arrow trending downward sharply

Image source: Getty Images.

Odonate had hoped that it would be able to win approval for tesetaxel after the experimental drug achieved its primary endpoint of progression-free survival in a late-stage study for treating metastatic breast cancer. However, the company met with the U.S. Food and Drug Administration (FDA) about the path for approval for the drug. After receiving feedback from the FDA, Odonate decided that the data for tesetaxel wasn't likely to win FDA approval.

Some companies try to pivot in another direction after encountering an obstacle as Odonate experienced. The problem, though, is that Odonate put all of its eggs in one basket with tesetaxel and has no other drug in its pipeline. 

Now what

Odonate said it plans to work with patients in its clinical study to transition to other therapies. After that, the company will shut down at some point in the near future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Odonate Therapeutics, Inc. Stock Quote
Odonate Therapeutics, Inc.
$1.52 (0.66%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.